Literature DB >> 25154

Plasma level monitoring of antipsychotic drugs.

T B Cooper.   

Abstract

Psychotic patients treated with identical doses of antipsychotic drugs have been shown to have great interindividual differences in their steady state plasma concentration. Therefore, monitoring treatment by dosage adjustment alone is of little value. If antipsychotic blood levels can be related to clinical response then their routine measurement may well result in well defined guidelines to individualised optimal dosage. Despite the considerable effort expended in this field and the many interesting testable hypotheses generated, little substantive evidence for an acceptable plasma level monitoring guide has been reported to date. Work on metabolite level profiles, intra- and extracellular drug concentration differences, more detailed clinical rating scales, and improved experimental design, all show great promise for the future. Investigation of the pharmacokinetics and the elucidation of the often complex metabolic pathways of individual antipsychotic drugs are generating the data base required for the rational pharmacotherapy of these most severely ill patients. Until more data are available, routine monitoring of antipsychotic drug plasma levels remains of research interest.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 25154     DOI: 10.2165/00003088-197803010-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  89 in total

1.  Thymoleptic and neuroleptic drug plasma levels in psychiatry: current status.

Authors:  T B Cooper; G M Simpson; J H Lee
Journal:  Int Rev Neurobiol       Date:  1976       Impact factor: 3.230

2.  Relationship of pharmacological models of bioavailability of chlorpromazine with drug and metabolite blood levels.

Authors:  R O Friedel
Journal:  Psychopharmacol Bull       Date:  1976-10

3.  Clinical significance of plasma chlorpromazine levels. II. Plasma levels of the drug, some of its metabolites and prolactin in patients receiving long-term phenothiazine treatment.

Authors:  T Kolakowska; D H Wiles; M G Gelder; A S McNeilly
Journal:  Psychopharmacology (Berl)       Date:  1976-08-26       Impact factor: 4.530

4.  Gas chromatographic identification of thioridazine in plasma, and a method for routine assay of the drug.

Authors:  S H Curry; G P Mould
Journal:  J Pharm Pharmacol       Date:  1969-10       Impact factor: 3.765

5.  Serum concentration and elimination from serum of thioridazine in psychiatric patients.

Authors:  R Axelsson; E Mårtensson
Journal:  Curr Ther Res Clin Exp       Date:  1976-02

6.  Butaperazine dimaleate metabolism.

Authors:  R B Bruce; L B Turnbull; J H Newman; J M Kinzie; P H Morris; F M Pinchbeck
Journal:  Xenobiotica       Date:  1974-04       Impact factor: 1.908

7.  [Therapeutic effect and plasma level of thioridazine in schizophrenic patients (author's transl)].

Authors:  H E Klein; O Chandra; N Matussek
Journal:  Pharmakopsychiatr Neuropsychopharmakol       Date:  1975-05

8.  Measurement of thioridazine in blood and urine.

Authors:  C H Ng; J L Crammer
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

9.  [Plasma levels of imipramine and desmethylimipramine and antidepressant effect during controlled therapy(author's transl)].

Authors:  R Oliver-Marti n; E Buschsenschultz; P Pichot; J Boissier
Journal:  Psychopharmacologia       Date:  1975

10.  Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels.

Authors:  L Rivera-Calimlim; H Nasrallah; J Strauss; L Lasagna
Journal:  Am J Psychiatry       Date:  1976-06       Impact factor: 18.112

View more
  17 in total

1.  Psychotherapeutic drugs: important adverse reactions and interactions.

Authors:  G D Burrows; T R Norman
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

Review 2.  Clinical relevance of pharmacokinetics.

Authors:  G Tognoni; C Bellantuono; M Bonati; M D'Incalci; M Gerna; R Latini; M Mandelli; M G Porro; E Riva
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

Review 3.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

4.  Binding of tricyclic antidepressants and perazine to human plasma. Methodology and findings in normals.

Authors:  M Brinkschulte; U Breyer-Pfaff
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-07       Impact factor: 3.000

Review 5.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

7.  Smoking and body weight influence the clearance of chlorpromazine.

Authors:  M Chetty; R Miller; S V Moodley
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Effect of calmodulin inhibitors on viability and mitochondrial potential of Plasmodium falciparum in culture.

Authors:  T G Geary; A A Divo; J B Jensen
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

9.  Pharmacokinetics of chlorpromazine and key metabolites.

Authors:  P K Yeung; J W Hubbard; E D Korchinski; K K Midha
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.

Authors:  L B Hansen; N E Larsen; P Vestergård
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.